- STAT+: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trialOtsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the benefit was less than expected.STAT · 1mo ago↗ source
- STAT+: Supreme Court backs generic drugmaker in ‘skinny labeling’ caseThe Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with implications for lawsuits over so-called skinny labels.STAT · 1mo ago↗ source
- STAT+: For pancreatic cancer patients, an exciting drug can feel out of reachFor pancreatic cancer patients, the surge in interest for an exciting new drug is leaving them fearful about when they might get the treatment or if there will be enough…